PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
204 hedge funds and large institutions have $946M invested in PDL BioPharma, Inc. in 2015 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 77 increasing their positions, 73 reducing their positions, and 27 closing their positions.
399% more call options, than puts
Call options by funds: $7M | Put options by funds: $1.4M
5% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 73
5% less funds holding
Funds holding: 215 → 204 (-11)
7% less capital invested
Capital invested by funds: $1.01B → $946M (-$69M)
30% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Gotham Asset Management
New York
|
+$25.9M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$22.9M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$15.8M |
| 4 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$7.15M |
| 5 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$4.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$11.8M |
| 2 |
Morgan Stanley
New York
|
-$6.11M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$5.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.83M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$3.51M |
PDLI Hedge Fund Activity: Q2 2015 in Review
204 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q2 2015, worth a combined $946M — down 6.8% from $1.01B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of PDLI and 19 opened new positions — a net loss of 8 holders — while 73 trimmed existing stakes and 77 added.
The largest buyer was Gotham Asset Management, adding an estimated $25.9M. The largest seller was Acadian Asset Management, cutting an estimated $11.8M.
- 204 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q2 2015, down from 215 in Q1 2015.
- Funds reported $946M of PDL BioPharma, Inc. stock for Q2 2015, down 6.8% quarter-over-quarter.
- 19 funds opened new PDL BioPharma, Inc. positions in Q2 2015 and 27 closed out, a net change of -8 holders.
- The largest PDL BioPharma, Inc. buyer in Q2 2015 was Gotham Asset Management, an estimated $25.9M added.
- The largest PDL BioPharma, Inc. seller in Q2 2015 was Acadian Asset Management, an estimated $11.8M sold.
Based on aggregated 13F filings for Q2 2015.